Indeed, NRF2 overexpression could play a cytoprotective role in cancer cells, regardless of p53 activation, which is one reason why the NRF2 pathway could be depicted as a molecular vulnerability to be therapeutically exploited. The gene discussed is TP53; the disease is cancer.